Ubrelvy (ubrogepant) / AbbVie 
Welcome,         Profile    Billing    Logout  
 6 Diseases   10 Trials   10 Trials   617 News 


12345678»
  • ||||||||||  Ubrelvy (ubrogepant) / AbbVie
    Journal, Real-world evidence, Real-world:  Ubrogepant users' real-world experience: Patients on ubrogepant, characteristics and outcomes (UNIVERSE) study. (Pubmed Central) -  Nov 13, 2024   
    Lasmiditan, rimegepant, and ubrogepant are effective for acute treatment of migraine in triptan-insufficient responders, with high-dose lasmiditan showing the highest efficacy for pain control. Ubrogepant demonstrated real-world effectiveness in the acute treatment of migraine, as evidenced by high levels of treatment satisfaction and a strong indication of their intent to continue using the medication.
  • ||||||||||  Sex/Gender Equity Considerations in Clinical Trials of Gepants for Migraine: A Systematic Review () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_989;    
    Despite the well-established gendered nature of disease and high proportions of women recruited, gepants trials for migraine did not appear to fulfil sex/gender health equity considerations in study design, conduct, analysis, and reporting. This oversight may affect the health technology assessment process leading to potential biases and inequities in healthcare recommendations and policies.
  • ||||||||||  Lu AG09222 / Lundbeck
    Enrollment open:  A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine (clinicaltrials.gov) -  Oct 1, 2024   
    P1,  N=40, Recruiting, 
    This oversight may affect the health technology assessment process leading to potential biases and inequities in healthcare recommendations and policies. Not yet recruiting --> Recruiting
  • ||||||||||  Ubrelvy (ubrogepant) / AbbVie
    FDA event, Journal:  A Case of Acute Migraine Without Aura Treated With a New FDA-Approved Medication Ubrogepant. (Pubmed Central) -  Sep 12, 2024   
    Her Migraine Disability Assessment (MIDAS) score showed moderate disability resulting in missed work and lower quality of life. To date, there have been no case reports showing the efficacy of the new FDA-approved medication, ubrogepant, showing a greater than 50% decrease in headache duration.
  • ||||||||||  Ubrelvy (ubrogepant) / AbbVie
    Enrollment closed, Trial primary completion date:  UNION: Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies (clinicaltrials.gov) -  Aug 19, 2024   
    P4,  N=164, Active, not recruiting, 
    This approach may have additional benefits for various groups of patients, including overweight patients. Recruiting --> Active, not recruiting | Trial primary completion date: May 2024 --> Sep 2024
  • ||||||||||  Ubrelvy (ubrogepant) / AbbVie, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    The use of Lifestyle Redesign () -  Jun 18, 2024 - Abstract #AHS2024AHS_429;    
    She was also prescribed Ubrelvy in 2021, but she did not find it as effective as sumatriptan...She started Botox in 2022 and PT in 2023 and considers it to be helpful. She had also started Zonisamide 100 mg in 2023 which improved migraine severity (6
  • ||||||||||  Which combination of comorbidity makes migraine treatment impossible? A graphical approach () -  Jun 18, 2024 - Abstract #AHS2024AHS_411;    
    Despite the diverse comorbidities considered, no combination of abortive or prevention medications was found to be entirely contraindicated for migraine patients. However, cardiac comorbidities such as uncontrolled hypertension or hypotension, prior coronary artery disease, and heart failure could significantly limit the possibility of abortive and preventive treatments.
  • ||||||||||  Elyxyb (celecoxib) / Dr. Reddy's, Collegium Pharma, Sorrento, Ubrelvy (ubrogepant) / AbbVie, Nurtec ODT (rimegepant ODT) / Pfizer
    Pain freedom with celecoxib oral solution, ubrogepant, and rimegepant through 4 hours postdose: Post hoc analysis in the acute treatment of migraine () -  Jun 18, 2024 - Abstract #AHS2024AHS_378;    
    Participants who were treated with celecoxib 120 mg oral solution achieved higher pain-free therapeutic gains than those who were treated with ubrogepant 100 mg or rimegepant 75 mg from 60 min through 3 h postdose. To achieve pain freedom with celecoxib oral solution, fewer patients may need to be treated, and they may have less likelihood of being harmed than with ubrogepant 100 mg or rimegepant 75 mg.
  • ||||||||||  Ubrelvy (ubrogepant) / AbbVie
    Milk and plasma pharmacokinetics of single-dose ubrogepant in healthy lactating women () -  Jun 18, 2024 - Abstract #AHS2024AHS_374;    
    Based on the low cumulative amount of ubrogepant excreted in breast milk and the low RID of 0.153%, ubrogepant can be considered, in the context of overall benefit/risk for the mother and infant, for the acute treatment of migraine in lactating women. FIGURE 1 Mean (SD) plasma and milk ubrogepant concentrations following a 100 mg single dose in healthy lactating women.
  • ||||||||||  Ubrelvy (ubrogepant) / AbbVie
    Characterization of prodromal symptoms in migraine: Results from the PRODROME trial () -  Jun 18, 2024 - Abstract #AHS2024AHS_203;    
    P3
    PRODROME trial data provide a comprehensive profile of prodromal symptoms and their severity; most common were sensitivity to light, fatigue, neck pain, sensitivity to sound, cognitive symptoms, and dizziness. Although rates varied across the individual prodromal symptoms, between 29.9% and 60.8% were reported to be moderate or severe in intensity.
  • ||||||||||  Ubrelvy (ubrogepant) / AbbVie, Qulipta (atogepant) / AbbVie
    Pharmacological characterization of ubrogepant and atogepant antagonism in adipocyte cell models () -  Jun 18, 2024 - Abstract #AHS2024AHS_180;    
    Agonist pharmacology profiles suggested that both human adipocytes and mouse 3T3-L1 adipocytes express a functional canonical CGRP receptor. Ubrogepant and atogepant are capable of antagonizing CGRP activity in both human adipocytes and mouse 3T3-L1 adipocytes.
  • ||||||||||  Ubrelvy (ubrogepant) / AbbVie
    PK/PD data, Journal:  Pharmacokinetics of Ubrogepant in Healthy Japanese and White Adults. (Pubmed Central) -  Jun 1, 2024   
    Systemic exposure was 20% lower in Japanese participants as compared with White participants, but this difference is unlikely to be clinically relevant. Single doses of ubrogepant (25-100
  • ||||||||||  Ubrelvy (ubrogepant) / AbbVie, Qulipta (atogepant) / AbbVie
    Trial completion date, Trial primary completion date, Real-world evidence, Real-world:  COBRA: An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult Participants (clinicaltrials.gov) -  Apr 16, 2024   
    P=N/A,  N=200, Recruiting, 
    Ubrogepant and atogepant are capable of antagonizing additional receptors in the calcitonin receptor family, beyond the canonical CGRP receptor. Trial completion date: Jun 2025 --> Sep 2025 | Trial primary completion date: Jun 2025 --> Sep 2025
  • ||||||||||  Journal:  Preventive Treatment of Migraine. (Pubmed Central) -  Apr 7, 2024   
    Six drugs targeting CGRP (four monoclonal antibodies and two gepants) are now available for the preventive treatment of episodic migraine in adults. The efficacy of CGRP-targeted medications in the acute and preventive treatment of migraine, together with good safety and tolerability, has led to the emergence of new approaches to preventive treatment.
  • ||||||||||  Enrollment open:  Migraine Medication Effects on Urinary Symptoms (clinicaltrials.gov) -  Mar 29, 2024   
    P=N/A,  N=200, Enrolling by invitation, 
    The efficacy of CGRP-targeted medications in the acute and preventive treatment of migraine, together with good safety and tolerability, has led to the emergence of new approaches to preventive treatment. Not yet recruiting --> Enrolling by invitation
  • ||||||||||  Ubrelvy (ubrogepant) / AbbVie
    Journal:  How early can we treat migraine attacks? A perspective based on prodrome. (Pubmed Central) -  Mar 13, 2024   
    The data highlight possible differential effects of CGRP targeted therapies in different patient populations and the need for increased understanding of CGRP neurobiology in men and women. In the PRODROME trial, Dodick et
  • ||||||||||  meloxicam/rizatriptan (AXS-07) / Axsome Therap
    EMERGE Study: An Open-label Evaluation of the Efficacy and Safety of AXS-07 (MoSEIC (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3413;    
    P3
    Participants must have been using an oral CGRP inhibitor (rimegepant or ubrogepant). This is the first study to investigate the effects of AXS-07 in patients with inadequate response to oral CGRP inhibitors, a difficult to treat patient population.
  • ||||||||||  The Safety and Efficacy of Dual Calcitonin Gene-related Peptide Therapies for Migraine Treatment (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3206;    
    The observed reduction in headache severity and frequency suggests a dual blockade is beneficial for migraine symptom control in selected patients. Safety regarding this treatment option is also supported by these findings; specifically, the small molecule antagonists appear to be the safest option to include in dual regimens.
  • ||||||||||  Ubrelvy (ubrogepant) / AbbVie
    Cerebrospinal Fluid and Plasma Concentrations of Ubrogepant in Participants with a History of Migraine (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3007;    
    Ubrogepant concentrations in the CSF are approximately 1% of plasma concentrations at 4 hours post-dose. Based on the results of pharmacodynamic assessments of the inhibition of capsaicin-induced increases in forearm dermal blood flow suggesting ubrogepant EC50 value of approximately 1.41 ng/mL, the CSF concentrations observed at 4 hours post-dose suggest that ubrogepant could act both centrally and peripherally to relieve migraine symptoms.